Literature DB >> 8306063

Thrombolytic effect of a plasminogen-plasminogen activator chimera in a photochemically induced thrombosis (PIT) model.

H Matsuno1, T Uematsu, M Nakashima.   

Abstract

The thrombolytic effects of the plasminogen/plasminogen activator chimera (SUN9216), comprising the fibrin-binding kringle 1 domain of plasminogen and two kringle and the serine protease domain of the wild-type tissue plasminogen activator (t-PA) including a modification of the mannose glycosylation on the kringle 1 of t-PA (PK1 delta FE1X), was compared with tht of t-PA by use of a photochemically induced thrombus (PIT) in the rat femoral artery. When SUN9216 was administered either as an i.v. infusion (1.0 mg kg-1) or as a single bolus i.v. injection (1.0 mg kg-1), all parameters were markedly improved compared to t-PA administered as an i.v. infusion (3.0 mg kg-1). A higher concentration of plasminogen activator (PA) activity in plasma was observed after administration of SUN9216 which persisted for longer than that after t-PA. It is concluded that the thrombolytic effect of SUN9216 is markedly greater than that of t-PA.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8306063      PMCID: PMC2175879          DOI: 10.1111/j.1476-5381.1993.tb13954.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  6 in total

1.  Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator.

Authors:  H Matsuno; T Uematsu; K Umemura; Y Takiguchi; K Wada; M Nakashima
Journal:  Br J Pharmacol       Date:  1992-07       Impact factor: 8.739

2.  Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi.

Authors:  S Suzuki; M Saito; N Suzuki; H Kato; N Nagaoka; S Yoshitake; H Mizuo; T Yuzuriha; Y Yui; C Kawai
Journal:  J Cardiovasc Pharmacol       Date:  1991-05       Impact factor: 3.105

3.  Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with use of this model.

Authors:  H Matsuno; T Uematsu; S Nagashima; M Nakashima
Journal:  J Pharmacol Methods       Date:  1991-07

4.  Functional effects of asparagine-linked oligosaccharide on natural and variant human tissue-type plasminogen activator.

Authors:  L Hansen; Y Blue; K Barone; D Collen; G R Larsen
Journal:  J Biol Chem       Date:  1988-10-25       Impact factor: 5.157

5.  Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombosis model.

Authors:  J P Clozel; T Tschopp; E Luedin; P Holvoet
Journal:  Circulation       Date:  1989-01       Impact factor: 29.690

6.  Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits.

Authors:  D Collen; J M Stassen; G Larsen
Journal:  Blood       Date:  1988-01       Impact factor: 22.113

  6 in total
  1 in total

1.  Comparative antiplatelet effects of aspirin, vapiprost and GR144053, a GPIIb/IIIa antagonist, with a special reference to the role of platelet microaggregates.

Authors:  H Matsuno; O Kozawa; S Nagashima; M Kanamaru; T Uematsu
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.